- Home
- ALT vs KOD Comparison
ALT vs KOD Comparison
Compare ALT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | KOD |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 1.4B |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ALT | KOD |
|---|---|---|
| Price | $3.33 | $22.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $17.67 | ★ $28.29 |
| AVG Volume (30 Days) | ★ 2.9M | 468.9K |
| Earning Date | 03-05-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.37 | ★ 32.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.91 | $1.92 |
| 52 Week High | $7.73 | $31.18 |
Technical Indicators
Market Signals| Indicator | ALT | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 31.61 | 42.77 |
| Support Level | $2.91 | $21.19 |
| Resistance Level | $4.25 | $29.17 |
| Average True Range (ATR) | 0.24 | 1.56 |
| MACD | -0.04 | -0.34 |
| Stochastic Oscillator | 0.48 | 24.66 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.